Oramed Pharmaceuticals, Inc.

How big is Oramed Pharmaceuticals, Inc.?

As of Jun 18, Oramed Pharmaceuticals, Inc. has a market capitalization of 88.24 million, with net sales of 2.00 million and a net loss of 28.28 million over the last four quarters. Shareholder's funds are 146.26 million, and total assets amount to 155.28 million.

As of Jun 18, Oramed Pharmaceuticals, Inc. has a market capitalization of 88.24 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 2.00 million for the latest four quarters, while the net profit during the same period was a loss of 28.28 million.<BR><BR>As of Dec 24, the balance sheet shows shareholder's funds of 146.26 million and total assets amounting to 155.28 million.

What does Oramed Pharmaceuticals, Inc. do?

Oramed Pharmaceuticals, Inc. is a micro-cap pharmaceutical company focused on developing oral treatments for diabetes. As of March 2025, it reported net sales of $2 million and a net loss of $8 million, with a market cap of $88.24 million.

Overview: <BR>Oramed Pharmaceuticals, Inc. is a pharmaceutical company engaged in the research and development of oral pharmaceutical solutions, particularly for diabetes treatment, and operates within the Pharmaceuticals & Biotechnology industry in the micro-cap market.<BR><BR>Financial Snapshot: <BR>Net Sales: 2 Million (Quarterly Results - Mar 2025) <BR>Net Profit: -8 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 88.24 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.93 <BR>Return on Equity: -20.08% <BR>Price to Book: 0.63<BR><BR>Contact Details: <BR>Address: 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY: 10036 <BR>Tel: 1 646 8441164 <BR>Fax: 1 845 8183588 <BR>Website: http://oramed.com

Should I buy, sell or hold Oramed Pharmaceuticals, Inc.?

Who are in the management team of Oramed Pharmaceuticals, Inc.?

As of March 2022, the management team of Oramed Pharmaceuticals, Inc. includes Kevin Rakin (Independent Chairman), Nadav Kidron (CEO), Miriam Kidron (Chief Scientific Officer), and several independent directors: Aviad Friedman, Xiaoming Gao, Arie Mayer, and Leonard Sank. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Oramed Pharmaceuticals, Inc. includes the following individuals:<BR><BR>- Mr. Kevin Rakin: Independent Chairman of the Board<BR>- Mr. Nadav Kidron: President, Chief Executive Officer, Director<BR>- Dr. Miriam Kidron: Chief Scientific Officer, Director<BR>- Mr. Aviad Friedman: Independent Director<BR>- Mr. Xiaoming Gao: Independent Director<BR>- Dr. Arie Mayer: Independent Director<BR>- Mr. Leonard Sank: Independent Director<BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Is Oramed Pharmaceuticals, Inc. overvalued or undervalued?

As of May 15, 2025, Oramed Pharmaceuticals, Inc. is considered risky and overvalued due to negative financial metrics, including a Price to Book Value of 0.64, an EV to EBITDA ratio of 2.81, and a -20.08% ROE, alongside significant underperformance compared to the S&P 500.

As of 15 May 2025, the valuation grade for Oramed Pharmaceuticals, Inc. has moved from does not qualify to risky. The company appears to be overvalued given its financial metrics, particularly with a Price to Book Value of 0.64 and an EV to EBITDA ratio of 2.81, which are concerning in the context of its negative returns. Additionally, the ROE stands at -20.08%, indicating significant inefficiencies in generating profit from equity.<BR><BR>In comparison to its peers, Esperion Therapeutics, Inc. shows a more severe valuation with an EV to EBITDA of -28.9150, while Protalix Biotherapeutics, Inc. is considered attractive with a P/E ratio of 20.0760. The stock has underperformed against the S&P 500 over the longer term, with a 3-year return of -68.23% compared to the S&P 500's 70.41%, reinforcing the notion that Oramed Pharmaceuticals is currently overvalued.

Is Oramed Pharmaceuticals, Inc. technically bullish or bearish?

As of September 11, 2025, Oramed Pharmaceuticals, Inc. shows a mildly bullish trend supported by positive MACD and Bollinger Bands, with a recent 17.31% monthly return, although it has underperformed over the past three years compared to the S&P 500.

As of 11 September 2025, the technical trend for Oramed Pharmaceuticals, Inc. has changed from sideways to mildly bullish. The weekly MACD is bullish, and the monthly MACD is mildly bullish, supporting the positive outlook. Bollinger Bands are bullish on both weekly and monthly time frames. The KST and OBV indicators are also mildly bullish monthly, while the daily moving averages indicate a mildly bearish stance. <BR><BR>In terms of performance, the stock has returned 17.31% over the past month, significantly outperforming the S&P 500's 2.33% return, but it has underperformed over longer periods, with a 3-year return of -68.23% compared to the S&P 500's 70.41%. Overall, the current technical stance is mildly bullish, driven primarily by the positive momentum in MACD and Bollinger Bands.